



Reply: Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery

Copyright ©The authors 2023.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 1 Dec 2022
Accepted: 5 Dec 2022



Reply to M. Ackermann and co-workers:

We thank M. Ackermann and co-workers for their interest in our recent publication [1]. These authors highlight our report of persistent increased alveolar dead space in 30% of 17 patients studied within ~2 months after an acute episode of mild–moderate COVID-19. After outlining their own work, demonstrating secondary pulmonary lobule pathologies found in the lungs of deceased COVID-19 patients, they then hypothesise that secondary lobular micro-ischaemia may be responsible for the elevated alveolar dead space found in our study.

Our study findings support persistent pulmonary vascular injury in recovered COVID-19 patients, for which M. Ackermann and co-workers provide pathological evidence. However, while we hypothesised that persistent microvascular obstruction was a likely explanation for the elevated alveolar dead space, M. Ackermann and co-workers provide an alternative and possibly complementary hypothesis linking functional and structural abnormalities. Both hypotheses, however, remain unproven, and the question of how the pathological findings from patients with fatal COVID-19 (provided by M. Ackermann and co-workers) relate to the functional physiological findings from patients recovered from an episode of mild–moderate COVID-19 (as in our study) remains unanswered. Resolving these issues will likely require a multidisciplinary approach combining physiological, pathological, radiological and interventional methodologies.

Shareable abstract (@ERSpublications)

Increased dead space following COVID-19 may be due to microvascular injury or secondary micro-ischaemia <https://bit.ly/3Fypdwz>

Cite this article as: Harbut P, Prisk GK, Lindwall R, *et al.* Reply: Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. *Eur Respir J* 2023; 61: 2202287 [DOI: 10.1183/13993003.02287-2022].

Piotr Harbut¹, G. Kim Prisk², Robert Lindwall¹, Sarah Hamzei¹, Jenny Palmgren¹, Catherine E. Farrow^{3,4,5}, Goran Hedenstierna^{6,†}, Terence C. Amis^{3,4,5}, Atul Malhotra², Peter D. Wagner² and Kristina Kairaitis^{3,4,5}

¹Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden. ²University of California, San Diego, CA, USA. ³Ludwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, Sydney, Australia. ⁴Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, Australia. ⁵Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. ⁶University of Uppsala, Uppsala, Sweden. [†]Deceased.

Corresponding author: Kristina Kairaitis (kristina.kairaitis@sydney.edu.au)

Conflict of interest: A. Malhotra has received grants from the National Institutes of Health, and consulting fees for medical education from Livanova, Equilibrium, Corvus and Jazz. P.D. Wagner has received consulting fees from SMS Biotechnology and Third Pole Inc., and has participated on the data safety monitoring board on Dr Levine's (UT Southwestern, Dallas, TX, USA) PPG. No other author has a conflict of interest to declare.

Reference

- 1 Harbut P, Prisk GK, Lindwall R, *et al.* Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. *Eur Respir J* 2023; 61: 2201117.